PerpEquities

Equity · Healthcare

McKesson Corporation (MCK) perpetual futures

MCK perpetual futures on 1 crypto exchanges – live perp price vs the stock, funding rate, open interest and where to trade MCKUSDT.

McKesson Corporation is a global healthcare services provider operating in the US and internationally, with four segments covering pharmaceutical distribution, medical-surgical supplies, and prescription technology solutions.

$1,061+7.0%NYSE closed
Open in terminal

Price chart

 

Use the left and right arrow keys to inspect points on the chart.

Collecting venue price data...
venue perp mark · MEXC (MCK/USDT)
Auto: highest-volume live perp venueOpen in TradingView

Trading data

Perpetual market activity

1/2 live markets
Venues
2
Live markets
1/2
24h volume
$109.9K
Open interest
$82.3K
Best liquidity
$0
MEXC
Tightest spread
+518.5 bps
MEXC
Highest volume
$109.9K
MEXC
Settlement mix
USDT · 2/2
Perp/spot vol.
0.00x
Spot volume $1.2B
OI / float
0.00%
Float $123.6B
Spot performance
1D+6.87%
5D+6.16%
1M+16.70%
6M+33.37%
YTD+30.24%
1Y+26.54%

Venue matrix

2 markets

Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.

Trade
MEXCTradeMCK/USDTTrading$1,061-14.8% APR
-0.014% every 8h		+518.5 bps$0$109.9K$82.3KUSDT20x
BingXTradeMCK-USDTWatchlist------USDT-

Tradability

Execution quality

Entry cost and depth per venue at $1k–$100k

No sufficient depth · 0 of 1 venues absorb $10k

No fresh book data: MEXC

Taker execution estimate incl. approx. fees - maker fills are not guaranteed.

Best venues for this underlying

Best liquidity

MCK
MEXC · MCK/USDT$0

Tightest spread

MCK
MEXC · MCK/USDT+518.5 bps

Highest volume

MCK
MEXC · MCK/USDT$109.9K

Funding history

Stored venue snapshots by market

Company financials

Financials at a glance

Last report Q2 '27 · filed 2026-11-04 · next report 2027-02-03 · Updated 10s ago
All financials →

Valuation & key figures

Market cap
$124.6B
Updated 10s ago
Revenue
$418.8B
Trailing 12 months
Revenue growth
+7%
Next fiscal year
Profit margin
+1.1%
P/E
27.4
Peer P/E 25.7
P/S
0.3
Peer P/E
25.7
Similar listed perps
Free cash flow
$7B
Trailing 12 months
Net income
$4.7B
Trailing 12 months
Revenue estimate
$431.9B
Next fiscal year
Earnings
2027-02-03
Revenue est. $113.3B · Updated 10s ago
Dividend
$0.94
2026-12-01
Revenue (TTM)$419B+8.2% vs a year agoLast 4 quarters; bars = each quarter
Operating margin (TTM)1.6%+0.4 pp vs a year agoOperating income $6.79B
Net income (TTM)$4.7B+16.5% vs a year agoAfter tax, incl. non-operating gains
Free cash flow (TTM)$7.03B+17.0% vs a year agoCapex $360M
Diluted EPS (TTM)$38.89+21.1% vs a year agoSum of the last 4 quarters
Net cash-$4.63B+18.5% vs a year agoCash + short-term investments - debt
  • Last report (2026-11-04): revenue beat by 1.0%, EPS beat by 9.0%Revenue $111B vs $110B expected (+1.0%); EPS $11.68 vs $10.72 (+9.0%).
  • Revenue growth slowing: 7.6% year on yearQ2 '27 revenue $111B, against an average of 8.8% over the four quarters before.
  • Operating margin 1.6% (TTM), +0.4 pp on a year agoOperating income grew 40.7% while revenue grew 8.2%.
  • Capex 0.1% of revenue (a year ago 0.2%)$360M invested in the last 4 quarters (-58.1% on a year earlier). Free cash flow $7.03B = 149.6% of net income.

Revenue, operating income and growth

quarterly

Segments in Q3 '25

from the filing
SegmentRevenuey/yOp. incomeMargin
US Pharmaceutical Segment$87.1B–$854M1.0%
International Segment$3.86B–$111M2.9%
Medical Surgical Solutions Segment$2.95B–$269M9.1%
Prescription Technology Solutions Segment$1.37B–$219M16.0%
In the full financialsIncome statement, balance sheet and cash flow (12 quarters / 10 years) · margins and cost structure · capital allocation and buybacks · valuation against the 5-year range · analyst estimates · all 282 lines McKesson Corporation reported to the SEC

Next catalyst

Catalysts

Earnings
2027-02-03
Revenue est. $113.3B · Updated 10s ago
Dividend
$0.94
2026-12-01

No unusual perp activity right now.

Research data

Analysts, filings and peer context

Estimates

6
DateEPS estimateRevenue estimateGrowthAnalysts
FY 202744.65$431.9B+7%9
FY 202850.62$461.3B+14%9
FY 202957.93$494.5B+23%4
FY 203066.48$515.5B+28%1
FY 203180.34$560.3B+39%2
Q2 202813.98$115.7B+4%9

Company events

6
2027-02-03EarningsActual - / Estimate 10.93-
2026-12-01Dividend$0.94-
2026-11-04Earnings · After market closeActual 11.68 / Estimate 10.72Beat
2026-09-01Dividend$0.94-
2026-08-05EarningsActual 9.93 / Estimate 9.56Beat
2026-06-01Dividend$0.82-

Peer comparison

Similar listed perps
NameMarket capP/SP/EProfit marginVenues
BMY$127.7B2.613.8+18.5%1MDT$134.3B3.625.7+13.9%9MDTSTOCK$134.3B3.625.7+13.9%1SYK$111.9B4.330.9+13.8%3VRTX$139.2B10.735.1+30.6%4MRNA$103.2B46.3-32.4-141.4%23HCA$102.5B1.357.5+8.6%2CVS$102.3B0.29.2+2.6%3

Company data

Company intelligence

Updated: Nov 2, 2026, 02:51 PM UTC

Company profile

Sector
Healthcare
Industry
Medical - Distribution
Chief executive
Brian S. Tyler
Employees
42,300
IPO date
Nov 10, 1994
Country
US
Exchange
New York Stock Exchange
Website
Altman Z-scorei5.91
Piotroski scorei7/9
Overall ratingiB-
Owner earningsi-$225.17M-$1.89 per share
ESG risk ratingiBIndustry rank: 4 out of 5

Rating factors

Return on equityi
1
Return on assetsi
4
Debt to equityi
1
Price to earningsi
3
Price to booki
1

Company press releases

McKesson Corporation Declares Quarterly DividendBusiness WireCD&R and McKesson Corporation Sign Agreement to Acquire Option Care HealthBusiness WireMcKesson Corporation Extends Pharmaceutical Distribution Agreement with CVS HealthBusiness WireMcKesson Corporation Announces Second Quarter Fiscal 2027 Earnings Release DateBusiness WirePRIVACY ALERT: AWKO Law LLP Investigating McKesson for Data Breach Affecting 284 Million Patient RecordsBusiness WireMcKesson Signs Agreement to Acquire Precision Medicine Group, LLCBusiness Wire

Congressional disclosures

Senate

House

Market cap history
$118.06B+20.2%Aug 26 – Oct 26
$98.18B$109.06B$119.94BHigh: $119.94B · 2026-10-19Low: $98.18B · 2026-08-03Latest: $118.06B · 2026-10-30Aug 26Sep 26Oct 26
Latest: $118.06B · 2026-10-30High: $119.94B · 2026-10-19Low: $98.18B · 2026-08-03
Largest fund holders
FundWeightShares held
BSCP0.34%7.9M
VTI0.14%3.7M
VOO0.15%3.1M
VCPA.S0.05%2M
IVV0.18%1.6M
1657.T0.14%1.6M
XSP.TO0.17%1.6M
XWD.TO0.12%1.6M
SPY0.17%1.4M
FXAIX0.15%1.3M
VTV0.38%1.1M
VSCA.S0.03%1M

Analyst track record

How the analysts covering MCK have done: ratings, price-target accuracy and the measured reaction after their calls.

12 months3 years
Ratings94288
Analysts1624
Buy / hold / sell77 / 17 / 0238 / 50 / 0
Upgrades / downgrades / initiations0 / 0 / 31 / 2 / 8
Price targets hit / missed47 / 39 (55%)225 / 39 (85%)
Avg. return after a rating (TipRanks)+1.8%+34.8%
Best / worst call+20.8% / -18.3%+118.0% / -18.3%

After buy calls on this stock: median 21-day move +2.8% vs S&P 500 +0.7% (n = 241)

Most accurate on this stock

Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.

  1. Erin WrightMorgan Stanley100% hit rate on this stock · 14 targets measuredBuytarget $1,207Oct 30, 2026
  2. Allen LutzBank of America Securities100% hit rate on this stock · 14 targets measuredBuytarget $1,250Nov 5, 2026
  3. Charles RhyeeTD Cowen100% hit rate on this stock · 14 targets measuredBuytarget $1,006Aug 6, 2026

Latest ratings

DateAnalystCallTarget
Nov 5, 2026Eric ColdwellRobert W. BairdBuyMaintained$1,225article ↗
Nov 5, 2026Allen LutzBank of America SecuritiesBuyReiterated$1,250article ↗
Nov 5, 2026Glen SantangeloBarclaysBuyMaintained$1,000article ↗
Oct 30, 2026Erin WrightMorgan StanleyBuyReiterated$1,207article ↗
Oct 20, 2026Steven ValiquetteMizuho SecuritiesHoldMaintained$1,020article ↗
Consensus over the last 12 months buy hold sell avg. target month-end close
Monthly buy, hold and sell shares of analyst ratings with the average price target and the month-end close$750$800$850$900$950$1,000Dec 25 · Buy 15 · Hold 2 · Sell 0Dec 25Jan 26 · Buy 14 · Hold 2 · Sell 0Feb 26 · Buy 13 · Hold 2 · Sell 0Feb 26Mar 26 · Buy 12 · Hold 2 · Sell 0Apr 26 · Buy 10 · Hold 2 · Sell 0Apr 26May 26 · Buy 11 · Hold 2 · Sell 0Jun 26 · Buy 11 · Hold 2 · Sell 0Jun 26Jul 26 · Buy 11 · Hold 2 · Sell 0Aug 26 · Buy 12 · Hold 3 · Sell 0Aug 26Sep 26 · Buy 12 · Hold 3 · Sell 0Oct 26 · Buy 13 · Hold 3 · Sell 0Oct 26Nov 26 · Buy 13 · Hold 3 · Sell 0Dec 25 · avg. target $916Jan 26 · avg. target $931Feb 26 · avg. target $972Mar 26 · avg. target $982Apr 26 · avg. target $965May 26 · avg. target $942Jun 26 · avg. target $931Jul 26 · avg. target $937Aug 26 · avg. target $979Sep 26 · avg. target $979Oct 26 · avg. target $1,005Nov 26 · avg. target $1,005Dec 25 · month-end close $820Jan 26 · month-end close $831Feb 26 · month-end close $987Mar 26 · month-end close $865Apr 26 · month-end close $815May 26 · month-end close $742Jun 26 · month-end close $756Jul 26 · month-end close $856Aug 26 · month-end close $885Sep 26 · month-end close $854Oct 26 · month-end close $995Nov 26 · month-end close $995

Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.

TipRanks data · computed Nov 5, 2026 · 94 ratings

Frequently asked questions

Where can I trade MCK perpetual futures?

McKesson Corporation (MCK) perpetual futures trade on 1 crypto venues, including MEXC. PerpEquities compares them by live price, funding rate, open interest and liquidity.

Can I trade MCK around the clock?

Yes. Unlike the underlying stock, MCK perpetuals trade 24/7 — including weekends and outside regular market hours.

What is the funding rate on MCK perpetuals?

Right now the MCK perp funding rate is -14.8% annualized (venue median), ranging from -14.8% to -14.8% across 1 venues. A positive rate means longs pay shorts. PerpEquities shows the live rate and its history for every venue.

How does the MCK perp price compare to the McKesson Corporation stock?

The venue-median MCK perp mark is $1.1K versus a reference stock price of $1.1K, a basis of 0.0%. Perps follow the stock through an index price; the gap widens when funding or liquidity diverge between venues.

What is a MCK perpetual future?

A MCK perpetual is a derivative that tracks the price of McKesson Corporation with no expiry date. It lets you take long or short exposure to McKesson Corporation on crypto venues, around the clock.

What is MCKUSDT perpetual?

MCKUSDT is the symbol most crypto exchanges use for the McKesson Corporation perpetual settled in USDT (Tether). It tracks the MCK share price through an index, trades 24/7 with leverage and never expires.

Other Healthcare perps

Also listed on MEXC

Embed this asset

MCK perpetuals · perpequities.comMCK perpetuals · perpequities.com
<a href="https://perpequities.com/stocks/mck-perp"><img src="https://perpequities.com/badge/mck-perp.svg" width="240" height="64" alt="MCK perpetuals · perpequities.com" loading="lazy"></a>

Raw data: JSON · CSV · API

Next step

Stay on top of MCK perps

Signals with a track record

Analysts who hit 70%+ of their targets on the perps we track, congress buys over $500k, 13F positions over $5M, funding spreads that have paid for days. Every post shows the evidence. Free, no sign-up.

Join on Telegram

Weekly digest by email

The listings, funding and moves that matter for MCK — one email every Sunday.

Watchlist and alerts

Price and funding alerts for MCK, via push or Telegram.

Set an alert

Follow the live feed

Daily movers, new listings and funding extremes as they happen.

Follow on X